X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SACT-1 (rilpivirine hydrochloride) is an orally administered repurposed small molecule drug for the treatment of neuroblastoma. SACT-1 enhance tumor cell death and suppress MYCN expression.
Lead Product(s): Rilpivirine Hydrochloride
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ALS-4 is a small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA. It targets antimicrobial resistant properties of the bacteria and is believed to render the bacteria highly susceptible to the host’s immune clearance.
Lead Product(s): ALS-4
Therapeutic Area: Infections and Infectious Diseases Product Name: ALS-4
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
NativusWell® contains a novel, non-hormonal bioactive ingredient DOI, having anti-ageing and antioxidant effect is designed to support the overall health of women undergoing perimenopause, menopause and postmenopause.
Lead Product(s): NativusWell
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NativusWell
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
SACT-1 (rilpivirine) is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated to enhance tumor cell death and suppress MYCN expression.
Lead Product(s): Rilpivirine
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aenco Technologies Limited
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 16, 2022
Details:
NativusWell (dioscorea polystachya) contains a novel, non-hormonal bioactive ingredient DOI, designed to support health of women undergoing perimenopause, menopause and postmenopause.
Lead Product(s): Dioscorea Polystachya
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NativusWell
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression.
Lead Product(s): SACT-1
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
USFDA has granted Orphan Drug Designation to SACT-1, an orally administered repurposed small molecule drug to target neuroblastoma on the basis of results that demonstrated enhanced tumor cell death and suppress MYCN expression in the preclinical studies.
Lead Product(s): SACT-1
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
Under the arrangement, Aptorum will be responsible for assessing Yale’s originally developed novel immunomodulators against lupus, arthritis, inflammatory bowel diseases, neurodegenerative diseases or other oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Yale University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 22, 2021
Details:
The primary objective of the trial is to evaluate the safety and tolerability of SAD and MAD of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
Lead Product(s): ALS-4
Therapeutic Area: Infections and Infectious Diseases Product Name: ALS-4
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
Aptorum Group intends to use the net proceeds to conduct further analyses of SACT-1 and ALS-4, currently on track for IND submission to commence Phase 1b/2a clinical trials and undergoing final stages of IND enabling studies for Phase 1 human clinical trials respectively.
Lead Product(s): SACT-1
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
